Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06217991
Other study ID # XKT-Y-20221148
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date December 30, 2025

Study information

Verified date January 2024
Source Tang-Du Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. To evaluate the safety, simplicity and effectiveness of the gastric function (anti-reflux) preservation of the innovative "parachute-tunnel-style technique" (PTST) in laparoscopic proximal gastrectomy. 2. To investigate the correlation between anastomotic stenosis and blood supply of serosa-muscle flap,suture after esophagogastric anastomosis.(obtain objective indexes such as blood supply, healing pattern and length change of serosa-muscle flap through animal experiments)


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date December 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Gastric cancer was confirmed histopathologically; - Patients who may undergo proximal gastrectomy according to guidelines; - Early upper gastric cancer, more than 1/2 of the distal gastric remnant remained after resection; - Esophagogastric junction carcinoma with maximum diameter =4 cm; - Patients with advanced upper gastric cancer (MSI-H) achieved cCR by neoadjuvant immunochemotherapy. Exclusion Criteria: - Patients with systemic conditions that cannot tolerate laparoscopic surgery; - Distal gastric remnant was less than 1/2 after proximal gastrectomy.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PTST(parachute-tunnel-style technique)for esophagogastrostomy
Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)

Locations

Country Name City State
China General Surgery Gastrointestinal Department,Tang-Du of Fourth Military Medical University Xi'an Shannxi Province

Sponsors (1)

Lead Sponsor Collaborator
Tang-Du Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary occurrence rate of anastomotic stenosis morbidity(%) one month after surgery
Primary occurrence rate of reflux esophagitis Visick score after surgery
Los Angeles rating
three month after surgery; six month after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05872295 - IKS014 in Advanced Solid Tumors That Express HER2 Phase 1
Recruiting NCT06101277 - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) N/A
Not yet recruiting NCT06093425 - Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Phase 3
Recruiting NCT04396821 - A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03526835 - A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02085564 - Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer N/A
Recruiting NCT05494060 - XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT05687357 - Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma Phase 2
Not yet recruiting NCT05447234 - TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy Early Phase 1
Recruiting NCT05439993 - Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma Phase 1/Phase 2
Recruiting NCT05480384 - Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction Phase 2
Recruiting NCT05858736 - Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors Phase 1
Recruiting NCT06121700 - Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer Phase 2
Not yet recruiting NCT05608785 - Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes Phase 1/Phase 2
Recruiting NCT05539430 - Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma Phase 1